Comparison of the Outcomes of Hepatocellular Carcinoma Patients Following Local Ablation Therapy and Hepatectomy
|
|
- Howard Barnett
- 6 years ago
- Views:
Transcription
1 Original Article Original Comparison of the Outcomes of Hepatocellular Carcinoma Patients Following Local Ablation Therapy and Kiyohide Kioka ) *, Takashi Nakai ), Yasuko Kawasaki ), Ayako Ueno 2), Yuhei Wakahara 2) Hirotsugu Maruyama 2), Shinsuke Hiramatsu 2), Takehisa Suekane 2), Tomoaki Yamasaki 2), Koji Sano 2) Eiji Sasaki 2), Hiroko Nebiki 2), Hiroshi Sato 2), Sadatoshi Shimizu 3), Akishige Kanazawa 3) Tadashi Tsukamoto 3), Yoichi Koda 4), Katsuko Murata 4), Takao Manabe 4) Comparison of the Outcomes of Hepatocellular Carcinoma Patients Following Local Ablation Therapy and Kiyohide Kioka ), Takashi Nakai ), Yasuko Kawasaki ), Ayako Ueno 2), Yuhei Wakahara 2), Hirotsugu Maruyama 2) Shinsuke Hiramatsu 2), Takehisa Suekane 2), Tomoaki Yamasaki 2), Koji Sano 2), Eiji Sasaki 2), Hiroko Nebiki 2), Hiroshi Sato 2) Sadatoshi Shimizu 3), Akishige Kanazawa 3), Tadashi Tsukamoto 3), Yoichi Koda 4), Katsuko Murata 4) and Takao Manabe 4) Abstract Of the 635 patients with hepatocellular carcinoma receiving initial treatment at our hospital, 297 received local ablation therapy and 592 underwent hepatectomy. The prognosis and background factors of these patients were compared in this study. No significant difference was noted in the cumulative survival rate between the local ablation therapy and hepatectomy groups. However, with regard to background factors, the local ablation therapy group had significantly poorer hepatic functional reserve, smaller tumor size, and a lower proportion of patients with progressive stage disease. Accordingly, further investigation was conducted in a similar manner to correct for these differences in background factors. We limited the target hepatocellular carcinoma patients to those with liver damage grade A and a single tumor of 2 cm. Although no difference was found in the cumulative survival rate between the local ablation therapy and hepatectomy groups, the cumulative non-recurrence survival rate was significantly more favorable in the latter. However, serum albumin levels were significantly lower and tumor size was smaller in patients who received local ablation therapy than in those who underwent hepatectomy, despite the inclusion of only those patients who met the aforementioned conditions of liver damage grade and tumor size. Similarly, the results of specific local ablation therapies, including percutaneous ethanol injection therapy, percutaneous microwave coagulation therapy, and percutaneous radiofrequency ablation, were compared with those of hepatectomy in patients with liver damage grade A and a single tumor of 2 cm in size. However, the results indicated no difference in the cumulative survival rate. In conclusion, the cumulative survival rate did not differ between patients who received local ablation therapy and those who underwent hepatectomy, even on limiting the subjects to patients with liver damage grade A and a single tumor of 2 cm. Key words: hepatocellular carcinoma, percutaneous microwave coagulation therapy, percutaneous ethanol injection therapy, percutaneous radiofrequency ablation, hepatectomy Accepted on July. 25, 23 Department of Hepatology ), Gastroenterology 2), Hepatobilliary and Pancreatic Surgery 3), and Radiology 4), Osaka City General Hospital Address: , Miyakojima-hondori, Miyakojima-ku, Osaka, 534-2, Japan *Author for correspondence and reprint requests: Kiyohide Kioka M.D., Ph.D. Department of Hepatology, Osaka City General Hospital Address: , Miyakojima-hondori, Miyakojima-ku, Osaka, 534-2, Japan TEL: FAX: J. Microwave Surg. Vol.3 No 23 33
2 Introduction Local ablation therapy has progressed from percutaneous ethanol injection therapy ) to percutaneous microwave coagulation therapy, 2) and more recently, many institutions perform percutaneous radiofrequency ablation. 3) Percutaneous microwave coagulation therapy was introduced in our hospital in 994 and percutaneous radiofrequency ablation was introduced in 2, primarily for the treatment of hepatocellular carcinoma involving a tumor of 3 cm. 4),5) In addition to these types of local ablation therapy, therapies such as hepatectomy and transcatheter arterial chemoembolization are used for the treatment of hepatocellular carcinoma. According to the liver cancer treatment algorithm described in the Guideline for liver cancer treatment based on scientific ground, the treatment method is determined according to the liver damage grade and the number and size of tumors. 6) Since the opening of our hospital in 994, the following principle has been followed for the treatment of hepatocellular carcinoma: hepatectomy for resectable cases; local ablation therapy for cases with tumor size and number of 3 cm and 3, respectively, and the possibility of securing a safety margin of approximately 5 mm around the tumor; and transcatheter arterial chemoembolization, as far as possible, for other cases. 4),5) The outcomes of patients who received local ablation therapy or hepatectomy as the initial treatment as per this algorithm were compared in this study. I. Patients and methods This study included 635 hepatocellular carcinoma patients who received initial treatment at our hospital between 994 and 2. Of these patients, 592 underwent hepatectomy, 344 received transcatheter arterial chemoembolization plus local ablation therapy, 336 received local ablation therapy, 228 received transcatheter arterial chemoembolization, received other treatment, and 25 did not receive treatment. Initially, the cumulative survival rate and cumulative nonrecurrence survival rate in these patients were compared according to the type of initial treatment. In the next step, the background factors and the cumulative survival rate/cumulative non-recurrence survival rate were compared between the 297 patients who had only received local ablation therapy (excluding the 39 patients who received concomitant local ablation therapy) and the 592 patients who underwent hepatectomy (Table.). Of the patients who received only local ablation therapy, 36, 59, and 2 received percutaneous ethanol injection therapy, percutaneous microwave coagulation therapy, and percutaneous radiofrequency ablation, respectively. Patients who received only local ablation therapy comprised 7 men and 26 women, and their mean age was 69±9 years. Patients who underwent hepatectomy comprised 443 men and 49 women, and their mean age was 67± years. Table. Background Factors of Hepatocellular Carcinoma Patients who Underwent or Local Ablation Therapy Factor Local ablation therapy (n=297) (n=592) P value Age 68.7± ±9.7 <. Sex (male/female) 7/26 443/49 <. Liver damage grade (A/B/C) 43/27/27 4/87/4 <. Child-Pugh grade (A/B/C) 26/77/4 54/5/ <. Stage (I/II/III/IV-A/IV-B) 88/87/2// 8/298/57/45/2 <. Tumor number (solitary/multiple) 23/66 39/22 <. Tumor size (mm) 8± 45±32 <. To correct for the differences in background factors between the local ablation therapy only group and the hepatectomy group, the target patients were limited to those with a single tumor of 2 cm in size. This was to allow direct comparisons between the local ablation therapy only group (2 patients) and the hepatectomy group (57 patients) (Table 2.). Furthermore, among those hepatocellular carcinoma patients with liver damage grade A and a single tumor of 2 cm, the cumulative survival rate of patients undergoing hepatectomy was compared with that of those who received only local ablation therapy (i.e., percutaneous ethanol injection therapy, percutaneous microwave coagulation therapy, or percutaneous radiofrequency ablation). The cumulative survival rate and cumulative nonrecurrence survival rate were calculated using the Kaplan- Meier method. For comparison of cumulative survival rate 34 J. Microwave Surg. Vol.3 No 23
3 Comparison of the Outcomes of Hepatocellular Carcinoma Patients Following Local Ablation Therapy and Table 2. C omparison of Background Factors of Hepatocellular Carcinoma Patients with Liver Damage Grade A and a Single Tumor of 2 cm between the and Local Ablation Therapy Groups Local ablation therapy (n=2) Factor (n=57) P value Age 68.7± ±8.9 <.5 Sex (male/female) 62/4 4/7 n.s. Albumin (g/dℓ) 3±.3 3.9± <.5 Prothrombin time (%) 92±4 95±5 n.s. Tumor size (mm) 5±3 7±3 <. n.s., not significant Similarly, no significant difference in the cumulative survival rate was noted between the 297 patients who received local ablation therapy only and the 592 patients who underwent hepatectomy (Figure 3), but the non-recurrence survival rate was more favorable in the latter (Figure 4). Comparison of the background factors showed that the local ablation therapy only group had a significantly poorer hepatic functional reserve, smaller tumors, and a lower proportion of patients with progressive stage disease (Table ). To correct for differences in background factors, and thus enable a direct comparison, the target patients were limited to those with liver damage grade A and a single tumor between the 2 groups, the log-rank test was employed. The of 2 cm. The results indicated no difference in the cumulative background factors between the 2 groups were compared survival rate between the local ablation therapy group and the using the χ2 test, Fisher s exact test, and the Mann-Whitney U hepatectomy group (Figure 5). However, the cumulative non- test. The results are presented as mean ± standard deviation, recurrence survival rate was more favorable in the latter and P<.5 was considered statistically significant. (Figure 6). However, serum albumin levels were significantly lower and tumor size was smaller in the local ablation therapy group than in the hepatectomy group, even when study II. Results Comparison of the cumulative survival rates among participants were limited to those patients who met the the initial treatment methods showed no significant difference aforementioned conditions (Table 2). The cumulative non- between the local ablation therapy group and the hepatectomy recurrence survival rates of patients who received group (Figure ). However, the cumulative non-recurrence percutaneous ethanol injection therapy, percutaneous survival rate was more favorable in the latter (Figure 2). m i c r o w a v e c o a g u l a t i o n t h e r a p y, a n d p e r c u t a n e o u s () (Other) (TAE) (TAE+) () (No treatment) 2 Other TAE TAE+ No treatment Figure. C umulative survival rate of hepatocellular carcinoma patients according to initial treatment types, as assessed using the KaplanMeier method Figure 2. C umulative non-recurrence survival rate of hepatocellular carcinoma patients according to initial treatment types *P<. vs. (log-rank test) : local ablation therapy : local ablation therapy TAE: transcatheter arterial chemoembolization TAE: transcatheter arterial chemoembolization J. Microwave Surg. Vol.3 No 23 35
4 Figure 3. s of hepatocellular carcinoma patients in the hepatectomy (n=592) and local ablation therapy (n=297) groups : local ablation therapy Figure 4. Cumulative non-recurrence survival rates of hepatocellular carcinoma patients in the hepatectomy (n=592) and local ablation therapy (n=297) groups *P<. vs. (log-rank test) : local ablation therapy Figure 5. s of hepatocellular carcinoma patients with liver damage grade A and a single tumor of 2 cm in the hepatectomy (n=592) and local ablation therapy (n=297) groups Figure 6. Cumulative non-recurrence survival rates of hepatocellular carcinoma patients with liver damage grade A and a single tumor of 2 cm in the hepatectomy (n=592) and local ablation therapy (n=297) groups *P<. vs. (log-rank test) : local ablation therapy 36 J. Microwave Surg. Vol.3 No 23
5 Comparison of the Outcomes of Hepatocellular Carcinoma Patients Following Local Ablation Therapy and Kaplan-Meier PEIT PMCT PRFA Figure 7. s of hepatocellular carcinoma patients with liver damage grade A and a single tumor of 2cm according to initial treatment types PEIT: percutaneous ethanol injection therapy PMCT: percutaneous microwave coagulation therapy PRFA: percutaneous radiofrequency ablation radiofrequency ablation were similarly compared with that of patients who underwent hepatectomy; no differences were noted between the groups (Figure 7). III. Discussion Treatment strategies for hepatocellular carcinoma vary from transhepatic arterial infusion chemotherapy to liver transplantation, as well as hepatectomy, local ablation therapy, and hepatic transcatheter arterial embolization. According to the liver cancer treatment algorithm described in the Guideline for liver cancer treatment based on scientific ground, the treatment method is determined according to the liver damage grade and the number and size of tumors. 6) In line with this algorithm, local ablation therapy is indicated for cases involving 3 tumors of 3 cm (also applicable to cases of hepatic disorder B and tumor size 2 cm, if a single tumor is present). At our hospital, the indication employed for percutaneous local ablation therapy is mostly according to the same treatment algorithm. Thus, for resectable cases, hepatectomy is selected, but local ablation therapy is indicated if the tumor size is 3 cm, if the number of tumors is 3, and if a safety margin of approximately 5 mm can be secured around the tumor. 4),5) Accordingly, local ablation therapy is not necessarily conducted if it is difficult to secure the safety margin, and hepatectomy is conducted in resectable cases. Further to these criteria, hepatectomy was performed in approximately 36% of all the hepatocellular carcinoma cases. This rate is slightly higher than the national mean value reported by the Liver Cancer Study Group of Japan. 7) Huang et al. 8) compared hepatectomy with percutaneous radiofrequency ablation for hepatocellular carcinoma cases corresponding to the Milan criteria. 9) They reported that both the survival rate and the non-recurrence survival rate were higher in the hepatectomy group. Further, Wang et al. ) compared hepatectomy with percutaneous radiofrequency ablation for hepatocellular carcinoma cases involving very early/early stage disease according to the BCLC staging system. ) They reported that, despite no difference in the survival rate, the non-recurrence survival rate was superior in the hepatectomy group. Takayama et al. 2) also compared hepatectomy with percutaneous radiofrequency ablation for hepatocellular carcinoma cases involving a single hepatocellular carcinoma smaller than 2 cm. They reported that the non-recurrence survival rate was higher in the hepatectomy group, although no difference was noted in the survival rate. In our study, we also evaluated hepatocellular carcinoma patients with liver damage grade A and a single tumor of 2 cm. Our results indicated a higher non-recurrence survival rate in the hepatectomy group than in the local ablation therapy group, despite there being no difference in the survival rate. However, the serum albumin levels were higher in the hepatectomy group, even when the target patients were limited to those with liver damage grade A. In addition, tumor size was smaller in the local ablation therapy group, even when selection was limited to patients with tumor size of 2 cm. Thus, the background factors were still different between these groups. In comparison with hepatectomy, local ablation therapy is less invasive and can be performed under more lenient standards of hepatic functional reserve; local ablation therapy can be indicated even for those with liver damage grade B. 6),3) However, localized control function following percutaneous radiofrequency ablation has been reported to be inferior to that following hepatectomy in patients with poorly differentiated tumors. 4) At our hospital, hepatectomy is usually selected for operable patients. However, patients with J. Microwave Surg. Vol.3 No 23 37
6 tumor below 3 cm in size, tumor number within 3, and availability of an approximately 5 mm safety margin around the tumor are considered indicated for local ablation therapy. Therefore, the use of the treatment algorithm employed at our hospital may achieve the favorable results. The merits of both hepatectomy and local ablation therapy should be considered, and the safest and most reliable treatment method should be selected without bias. Conclusion The cumulative survival rate did not differ significantly between the local ablation group and the hepatectomy group, even when the target patients were limited to those with liver damage grade A and a single tumor of 2 cm. Accordingly, evaluation of the merits of both hepatectomy and local ablation therapy is considered important in the treatment of hepatocellular carcinoma, and the safest and most reliable treatment method should be selected without bias. References ) Shiina S, Tagawa K, Unuma T, Takahashi R, Yoshimura K, Komatsu Y, Hata Y, Niwa Y, Shiratori Y, Terano A : Percutaneous ethanol injection therapy for hepatocellular carcinoma ; A histopathologic study. Cancer 68:524-53, 99 2) Seki T, Wakabayashi M, Nakagawa T, Itho T, Shiro T, Kunieda K, Sato M, Uchiyama S, Inoue K: Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 74:87-825, 994 3) Rossi S, Di Stasi M, Buscarini E, Cavanna L, Quaretti P, Squassante E, Garbagnati F, Buscarini L: Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am : 73-8, 995 4) So K, Kioka K, Moriyoshi Y, Oka H, Harihara S, Lee M, Yamasaki O, Murata K, Manabe T, Kuroki T, Kobayashi K : Assessment of the efficacy of microwave coagulation therapy for hepatocellular carcinoma by imaging techniques(in Japanese). Kanzo 37:563-57, 996 5) Kioka K, Kawasaki Y, Nakai T, Ishida Y, Maruyama H, Hiramatsu S, Mori A, Suekane T, Yamasaki T, Sano K, Shiba M, Nebiki H, Sato H, Shimizu S, Kanazawa A, Tsukamoto T : Investigation of different methods, particularly percutaneous ablation therapy, for treating non-b, non-c hepatocellular carcinoma. J Microwave Surg 29:99-4, 2 6) Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, Saida Y, Takayama T, Yamaoka Y : Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 38:37-5, 27 7) Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Yamaoka Y : Report of the 6th follow-up survey of primary liver cancer. The Liver Cancer Study Group of Japan. Hepatol Res 32:63-72, 25 8) Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. : A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 252:93-92, 2 9) Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 334: , 996 ) Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. : Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 56:42-48, 22 ) Llovet JM, Brú C, Bruix J.:Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 9: , 999 2) Takayama T, Makuuchi M, Hasegawa K. : Single HCC smaller than 2 cm: surgery or ablation?: surgeon's perspective. J Hepatobiliary Pancreat Sci. 7: , 2 3) Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R.:Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 32: , 2 4) Imamura J, Tateishi R, Shiina S, Goto E, Sato T, Ohki T, Masuzaki R, Goto T, Yoshida H, Kanai F, Hamamura K, Obi S, Yoshida H, Omata M. :Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol. 3: , J. Microwave Surg. Vol.3 No 23
Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma
Hiroshima J. Med. Sci. Vol. 47, No.4, 151~155, December, 1998 HIJM47-2 151 Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma Toshimasa ASAHARA1l, Hideki NAKAHARA1l, Toshikatsu FUKUDA1l,
More informationSurvival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis
2235-1795/16/0053-0175$39.50/0 175 Original Paper Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis Satoshi Kitai a Masatoshi Kudo a Naoshi Nishida a
More informationPostoperative recurrence in hepatocellular carcinoma: Comparison between percutaneous ethanol injection and radiofrequency ablation
Hepatology Research 36 (2006) 143 148 Postoperative recurrence in hepatocellular carcinoma: Comparison between percutaneous ethanol injection and radiofrequency ablation Kaoru Iwata, Tetsuro Sohda, Shinya
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationAvailable online at journal homepage:
Journal of the Formosan Medical Association (2012) 111, 510e515 Available online at www.sciencedirect.com journal homepage: www.jfma-online.com ORIGINAL ARTICLE The influence on liver function after transcatheter
More informationSurvival Difference between Surgery Versus Non-Surgery for the Treatment of Hepatocellular Carcinoma Patients at Liver Centre, Malaysia
Original Research Article Survival Difference between Surgery Versus Non-Surgery for the Treatment of Hepatocellular Carcinoma Patients at Liver Centre, Malaysia Azmawati MN 1 ( ), Azmi MT 1, Krishnan
More informationINTRODUCTION. Jpn J Clin Oncol 1997;27(4)
Jpn J Clin Oncol 1997;27(4)251 257 Therapeutic Results of Resection, Transcatheter Arterial Embolization and Percutaneous Transhepatic Ethanol Injection in 3225 Patients with Hepatocellular Carcinoma:
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Prognosis of Patients with Hepatocellular Carcinoma Treated Solely with Transcatheter Arterial Chemoembolization: Risk Factors for One-year Recurrence and Two-year Mortality (Preliminary
More informationPolicy Forum. The management of hepatocellular carcinoma in Asia: A guideline combining quantitative and qualitative evaluation
BioScience Trends. 2010; 4(6):283-287. 283 Policy Forum The management of hepatocellular carcinoma in Asia: A guideline combining quantitative and qualitative evaluation Peipei Song 1, Wei Tang 1, *, Sumihito
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationTakahito Nakagawa, MD, Toshiya Kamiyama, MD, Kazuaki Nakanishi, MD, Hideki Yokoo, MD, Hirofumi Kamachi, MD, Michiaki Matsushita, MD, Satoru Todo, MD
Pulmonary for metastases from hepatocellular carcinoma: Factors influencing prognosis Takahito Nakagawa, MD, Toshiya Kamiyama, MD, Kazuaki Nakanishi, MD, Hideki Yokoo, MD, Hirofumi Kamachi, MD, Michiaki
More informationClinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe
2235-1795/15/0042-0085$39.50/0 85 Editorial Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe Prof. M. Kudo Editor Liver Cancer Introduction Hepatocellular
More informationUsefulness of Resection for Hepatocellular Carcinoma with Macroscopic Bile Duct Tumor Thrombus
Usefulness of Resection for Hepatocellular Carcinoma with Macroscopic Bile Duct Tumor Thrombus ATSUSHI OBA 1, SHINICHIRO TAKAHASHI 1, YUICHIRO KATO 1, NAOTO GOTOHDA 1, TAKAHIRO KINOSHITA 1, HIDEHITO SHIBASAKI
More informationSafety and Efficacy of Radiofrequency Ablation with Artificial Ascites for Hepatocellular Carcinoma
212 66 3 279284 Safety and Efficacy of Radiofrequency Ablation with Artificial Ascites for Hepatocellular Carcinoma a a,b a* a a a a c a b c 28 66 3 ʼ Characteristics of HCC patients treated by RFA. Complete
More informationA Case of Advanced Multiple Hepatocellular Carcinomas with Portal Vein Tumor Thrombosis Successfully Treated by Oral Tegafur/Uracil
Journal of Cancer Therapy, 2010, 1, 160-164 doi:10.4236/jct.2010.13025 Published Online September 2010 (http://www.scirp.org/journal/jct) A Case of Advanced Multiple Hepatocellular Carcinomas with Portal
More informationMITSURU ISHIZUKA, KEIICHI KUBOTA, MITSUGI SHIMODA, JUNJI KITA, MASATO KATO, KYUNG HWA PARK and TAKAYUKI SHIRAKI
Effect of Menatetrenone, a Vitamin K 2 Analog, on Recurrence of Hepatocellular Carcinoma after Surgical Resection: A Prospective Randomized Controlled Trial MITSURU ISHIZUKA, KEIICHI KUBOTA, MITSUGI SHIMODA,
More informationHeterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage B
2235-1795/16/0052-0091$39.50/0 91 Editorial Heterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage B Prof. M. Kudo Editor Liver Cancer Intermediate-stage hepatocellular carcinoma (HCC)
More informationHepatocellular carcinoma (HCC) is a common. Prediction of Recurrence of Hepatocellular Carcinoma After Curative Ablation Using Three Tumor Markers
Prediction of Recurrence of Hepatocellular Carcinoma After Curative Ablation Using Three Tumor Markers Ryosuke Tateishi, Shuichiro Shiina, Haruhiko Yoshida, Takuma Teratani, Shuntaro Obi, Noriyo Yamashiki,
More informationCLINICAL LIVER, PANCREAS, AND BILIARY TRACT
GASTROENTEROLOGY 2008;134:1908 1916 BILIARY TRACT Neither Multiple Tumors Nor Portal Hypertension Are Surgical Contraindications for Hepatocellular Carcinoma TAKEAKI ISHIZAWA, KIYOSHI HASEGAWA, TAKU AOKI,
More informationPercutaneous Ethanol Injection Therapy in the Treatment of Hepatocarcinoma Results Obtained from a Series of 88 Cases
Percutaneous Ethanol Injection Therapy in the Treatment of Hepatocarcinoma Results Obtained from a Series of 88 Cases Mirela Danila, Ioan Sporea, Roxana Sirli, Alina Popescu Department of Gastroenterology
More informationLong-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma
Online Submissions: wjg.wjgnet.com World J Gastroenterol 2008 April 7; 14(13): 1997-2002 World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com 2008 WJG. All rights reserved. LIVER CANCER Long-term
More informationOver the past 20 years, great progress has been made in the
ORIGINAL ARTICLES Staging of Hepatocellular Carcinoma Assessment of the Japanese TNM and AJCC/UICC TNM Systems in a Cohort of 13,772 Patients in Japan Masami Minagawa, MD, PhD,* Iwao Ikai, MD, PhD,* Yutaka
More informationdoi: /hepr Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)
bs_bs_banner Hepatology Research 2016; 46: 3 9 doi: 10.1111/hepr.12542 Special Report Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version) Masatoshi Kudo, Kazuomi Ueshima,
More informationPrognostic Significance of Simultaneous Measurement of Three Tumor Markers in Patients With Hepatocellular Carcinoma
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:111 117 Prognostic Significance of Simultaneous Measurement of Three Tumor Markers in Patients With Hepatocellular Carcinoma HIDENORI TOYODA,* TAKASHI KUMADA,*
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationChapter 4 Percutaneous Ablation Therapy
Chapter 4 Percutaneous Ablation Therapy Introduction Over the past quarter of a century, various methods have been developed as local therapies for HCC. In 1979, Yamada et al. developed transcatheter arterial
More informationYuko Takami Tomoki Ryu Yoshiyuki Wada Hideki Saitsu
J Hepatobiliary Pancreat Sci (2013) 20:332 341 DOI 10.1007/s00534-012-0527-5 ORIGINAL ARTICLE Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single
More informationLiving donor liver transplantation for patients with hepatocellular carcinoma in Japan
Sugawara et al. Hepatoma Res 2018;4:33 DOI: 10.20517/2394-5079.2018.69 Hepatoma Research Review Open Access Living donor liver transplantation for patients with hepatocellular carcinoma in Japan Yasuhiko
More informationInterventional Radiologic Treatment of Hepatocellular Carcinoma
Interventional Radiologic Treatment of Hepatocellular Carcinoma Fatih Boyvat Abstract The current treatment modalities for patients with hepatocellular carcinoma are discussed in this review. Hepatocellular
More informationSurgical Treatment for Hepatocellular Carcinoma
Review Article Jpn J Clin Oncol 2011;41(4)447 454 doi:10.1093/jjco/hyr016 Advance Access Publication 16 March 2011 Surgical Treatment for Hepatocellular Carcinoma Tadatoshi Takayama * Department of Digestive
More informationINTRODUCTION. Tae Yong Park, Young Chul Na, Won Hee Lee, Ji Hee Kim, Won Seok Chang, Hyun Ho Jung, Jong Hee Chang, Jin Woo Chang, Young Gou Park
ORIGINAL ARTICLE Brain Tumor Res Treat 2013;1:78-84 / Print ISSN 2288-2405 / Online ISSN 2288-2413 online ML Comm Treatment Options of Metastatic Brain Tumors from Hepatocellular Carcinoma: Surgical Resection
More informationCirrhotic patients with solitary hepatocellular carcinoma
ORIGINAL ARTICLES Survival of Cirrhotic Patients With Early Hepatocellular Carcinoma Treated by Percutaneous Ethanol Injection or Liver Transplantation Angelo Andriulli, 1 Ilario de Sio, 2 Luigi Solmi,
More informationLong-term Results of Percutaneous Ethanol Injection for the Treatment of Hepatocellular Carcinoma in Korea
Long-term Results of Percutaneous Ethanol Injection for the Treatment of Hepatocellular Carcinoma in Korea Yon Mi Sung, MD 1,2 Dongil Choi, MD 1 Hyo K. Lim, MD 1 Won Jae Lee, MD 1 Seung Hoon Kim, MD 1
More informationLaparoscopic liver resection of hepatocellular carcinoma
The American Journal of Surgery 189 (2005) 190 194 Laparoscopy Laparoscopic liver resection of hepatocellular carcinoma Hironori Kaneko, M.D.*, Sumito Takagi, M.D., Yuichiro Otsuka, M.D., Masaru Tsuchiya,
More informationVery early stage hepatocellular carcinoma (HCC),
Hepatic Resection Versus Radiofrequency Ablation for Very Early Stage Hepatocellular Carcinoma: A Markov Model Analysis Yun Ku Cho, 1 Jae Kyun Kim, 2 Wan Tae Kim, 1 and Jin Wook Chung 3 No adequate randomized
More informationLONG-TERM SURVIVAL OF TAIWANESE PATIENTS WITH HEPATOCELLULAR CARCINOMA AFTER COMBINATION THERAPY
Chemoembolization/Percutaneous Ethanol Combination in HCC ORIGINAL ARTICLES LONG-TERM SURVIVAL OF TAIWANESE PATIENTS WITH HEPATOCELLULAR CARCINOMA AFTER COMBINATION THERAPY WITH TRANSCATHETER ARTERIAL
More informationTwo Rare Metachronous Metastases of Hepatocellular Carcinoma After Liver Transplantation
Int Surg 2013;98:432 436 DOI: 10.9738/INTSURG-D-13-00026.1 Case Report Two Rare Metachronous Metastases of Hepatocellular Carcinoma After Liver Transplantation Satoshi Shinya 1, Tomoaki Noritomi 1, Yasushi
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationThe most prominent etiological factors associated with hepatocellular
ORIGINAL ARTICLE A Comparison of the Surgical Outcomes Among Patients With -positive, -positive, and Non-B Non-C Hepatocellular Carcinoma A Nationwide Study of 11,95 Patients Tohru Utsunomiya, MD, PhD,
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationIVR TAE CT. Real-time Vertial Sonography(RVS) CT-MPR Realtime
IVR TAE CT Real-time Vertial Sonography(RVS)CT-MPRRealtime In the treatment of hepatocellular carcinoma, which often recurrents at the high rate, interventional radiology (IVR), a minimally invasive technique,
More informationHepatocellular Carcinoma
PSH Clinical Guidelines Statement 2017 Hepatocellular Carcinoma Dr. Zia ud Din Associate professor of medicine Lady Reading Hospital Peshawar INTRODUCTION Hepatocellular carcinoma is the primary liver
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationCombined therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation for small hepatocellular carcinoma
Online Submissions: wjg.wjgnet.com World J Gastroenterol 2009 February 14; 15(6): 748-752 wjg@wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 doi:10.3748/wjg.15.748 2009 The WJG Press and Baishideng.
More informationSuccessful Treatment of Hepatocellular Carcinoma with Lung Metastasis Using Hepatic and Bronchial Artery Infusion Chemotherapy
CASE REPORT Successful Treatment of Hepatocellular Carcinoma with Lung Metastasis Using Hepatic and Bronchial Artery Infusion Chemotherapy Tatsuki Yoshida 1,KentaroKamada 1, Kouichi Miura 1, Takashi Goto
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationPercutaneous Local Ablation Therapy in Small Hepatocellular Carcinoma. Shi-Ming Lin, MD; Deng-Yn Lin, MD
Review Article 308 Percutaneous Local Ablation Therapy in Small Hepatocellular Carcinoma Shi-Ming Lin, MD; Deng-Yn Lin, MD Periodic screening programs conducted in various countries, applying sonography
More informationEarly detection and characterization of hepatocellular. Early Detection and Curative Treatment of Early-Stage Hepatocellular Carcinoma
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:S144 S148 Early Detection and Curative Treatment of Early-Stage MASATOSHI KUDO Department of Gastroenterology and Hepatology, Kinki University School of
More informationHigh-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins
Eur Radiol DOI 10.1007/s00330-008-1137-0 ONCOLOGY Lian Zhang Hui Zhu Chengbin Jin Kun Zhou Kequan Li Haibing Su Wenzhi Chen Jin Bai Zhibiao Wang High-intensity focused ultrasound (HIFU): effective and
More informationResective surgery, when feasible, is considered the
Sustained Complete Response and Complications Rates After Radiofrequency Ablation of Very Early Hepatocellular Carcinoma in Cirrhosis: Is Resection Still the Treatment of Choice? Tito Livraghi, 1 Franca
More informationSignificance of Hepatectomy for AJCC/UICC T3 Hepatocellular Carcinoma
Significance of Hepatectomy for AJCC/UICC T3 Hepatocellular Carcinoma TOSHIYA OCHIAI 1,2, HIROMICHI ISHII 1, YUSUKE YAMAMOTO 2, RYO MORIMURA 2, HISASHI IKOMA 2 and EIGO OTSUJI 2 1 Department of Surgery,
More informationINTERNATIONAL JOURNAL OF ONCOLOGY 31: ,
INTERNATIONAL JOURNAL OF ONCOLOGY 31: 485-491, 2007 485 Clinicopathologic study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationAlthough hepatocellular carcinoma (HCC) with lymph node
ORIGINAL ARTICLE Impact of Histologically Confirmed Lymph Node Metastases on Patient Survival After Surgical Resection for Hepatocellular Carcinoma Report of a Japanese Nationwide Survey Kiyoshi Hasegawa,
More information간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung
간암의다양한병기분류법 : 현재사용중인병기분류를중심으로 Kim, Beom Kyung Importance of staging system 환자의예후예측 적절한치료방법적용 ( 수술, 방사선, 항암..) 의료진간의 tumor burden 에대한적절한의사소통 향후연구및 clinical trial 시연구집단의성격에대한객관적기준제시 Requisites for good staging
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationNegative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma
Li et al. World Journal of Surgical Oncology (2015) 13:294 DOI 10.1186/s12957-015-0713-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Negative impact of low body mass index on liver cirrhosis
More informationThoracoscopic Microwave Coagulation Therapy for Hepatocellular Carcinoma
Hiroshima J. Med. Sci. Vol. 47, No.3, 125-131, Septe~ber, 1998 HIJM47-19 125 Thoracoscopic Microwave Coagulation Therapy for Hepatocellular Carcinoma ToshimasaASAHARA1l, Koji KATAYAMA 1 l, Toshiyuki ITAMOTQ
More informationHepatocellular carcinoma (HCC) is the most
Original Article / Biliary Hepatobiliary & Pancreatic Diseases International Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection: a matched study Ding-Ding Wang, Li-Qun
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationDisclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report:
Disclosure Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company
More informationTriple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/25864747 Triple positive tumor markers predict recurrence and survival in early stage hepatocellular
More informationPercutaneous ablation: indications, techniques and results
Percutaneous ablation: indications, techniques and results Giovan Giuseppe Di Costanzo Dipartimento dei Trapianti UOSC Epatologia AORN A Cardarelli - Napoli Treatment algorithm EASL, EORTC guidelines HCC
More informationSingle Hepatocellular Carcinoma Smaller than 2 cm: Are Ethanol Injection and Radiofrequency Ablation Equally Effective?
Single Hepatocellular Carcinoma Smaller than 2 cm: Are Ethanol Injection and Radiofrequency Ablation Equally Effective? MAURIZIO POMPILI 1, NICOLETTA DE MATTHAEIS 1, ANTONIO SAVIANO 1, ILARIO DE SIO 2,
More informationHepatocellular carcinoma (HCC) is one of the
Radiofrequency Ablation for Hepatocellular Carcinoma in So-Called High-Risk Locations Takuma Teratani, Haruhiko Yoshida, Shuichiro Shiina, Shuntaro Obi, Shinpei Sato, Ryosuke Tateishi, Norio Mine, Yuji
More informationExtending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma
LIVER TRANSPLANTATION 13:S48-S54, 27 SUPPLEMENT Extending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma Satoru Todo, 1 Hiroyuki Furukawa, 2 Mitsuhiro Tada, 3 and the
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationRADIATION SEGMENTECTOMY. Robert J Lewandowski, MD
RADIATION SEGMENTECTOMY Robert J Lewandowski, MD Robert Lewandowski, M.D. Consultant/Advisory Board: Cook Medical, LLC, Arsenal, BTG International, Boston Scientific Corp., ABK Reference Unlabeled/Unapproved
More informationSurvival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification
Kamiyama et al. World Journal of Surgical Oncology (2017) 15:156 DOI 10.1186/s12957-017-1229-x RESEARCH Open Access Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification
More informationNucleotide Analogs for Patients with HBV-Related Hepatocellular Carcinoma Increase the Survival Rate through Improved Liver Function
ORIGINAL ARTICLE Nucleotide Analogs for Patients with HBV-Related Hepatocellular Carcinoma Increase the Survival Rate through Improved Liver Function Masahiko Koda 1, Takakazu Nagahara 1, Tomomitu Matono
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More informationPercutaneous Ablation Therapy for Hepatocellular Carcinoma: Current Practice and Future Perspectives
REVIEW ARTICLE Percutaneous Ablation Therapy for Hepatocellular Carcinoma: Current Practice and Future Perspectives Teh-Ia Huo 1,2 *, Yi-Hsiang Huang 1,2, Jaw-Ching Wu 1,3 1 National Yang-Ming University
More informationA small hepatocellular carcinoma (HCC) can be detected
1151 LIVER Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of
More informationUniversity Medical Center, Kyungpook National University School of Medicine, Daegu, Korea
Ann Hepatobiliary Pancreat Surg 2016;20:159-166 https://doi.org/10.14701/ahbps.2016.20.4.159 Original Article Impact of clinically significant portal hypertension on surgical outcomes for hepatocellular
More informationA A-a 1. Adachi T, Tajima Y, Kuroki T, Mishima T, Kitasato A, Tsuneoka N, Kanematsu T: Chemopreventive effects of a selective cyclooxygenase-2
A A-a 1. Adachi T, Tajima Y, Kuroki T, Mishima T, Kitasato A, Tsuneoka N, Kanematsu T: Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary
More informationPEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good
Reviewer s code: 03656588 Reviewer s country: China Date reviewed: 2017-06-08 [ ] Grade A: Excellent [ Y] Accept [ ] Grade B: Very good [ ] High priority for [ Y] Grade C: Good language [ ] Major revision
More informationScreening for hepatocellular carcinoma (HCC) is controversial.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:508 512 Screening for Hepatocellular Carcinoma Among Veterans With Hepatitis C on Disease Stage, Treatment Received, and Survival LUCI K. LEYKUM,* HASHEM
More informationTransarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular Carcinoma
DOI:10.22034/APJCP.2017.18.1.189 Combined TACE and MWA or RFA for HCC RESEARCH ARTICLE Transarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular
More informationTumor Response to Transcatheter Arterial Chemoembolization in Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation
Tumor Response to Transcatheter Arterial Chemoembolization in Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation Heung-Kyu Ko, MD 1 Gi-Young Ko, MD 2 Hyun Ki Yoon, MD 2 Kyu-Bo
More informationReview Article. Dig Dis 2015;33: DOI: /
Review Article General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer
More informationORIGINAL ARTICLE. Impact of Histological Grade of Hepatocellular Carcinoma on the Outcome of Liver Transplantation
ORIGINAL ARTICLE Impact of Histological Grade of Hepatocellular Carcinoma on the Outcome of Liver Transplantation Sumihito Tamura, MD; Tomoaki Kato, MD; Mariana Berho, MD; Evangelos P. Misiakos, MD; Christopher
More informationStaging and treatment of hepatocellular carcinoma
Multimodal Image-Guided Tailored Therapy of Early and Intermediate Hepatocellular Carcinoma: Long-Term Survival in the Experience of a Single Radiologic Referral Center Tito Livraghi, 1 Franca Meloni,
More informationRisk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma
720863TUB0010.1177/1010428317720863Tumor BiologyHong et al. research-article20172017 Original Article Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma Tumor Biology
More informationSIR- RFS Journal Primer
Comparison of Combina-on Therapies in the Management of Hepatocellular Carcinoma: Transarterial Chemoemboliza-on with Radiofrequency Abla-on versus Microwave Abla-on SIR- RFS Journal Primer Quick Summary
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More informationSurgical resection for hepatocellular carcinoma (HCC)
Surgical resection for hepatocellular carcinoma (HCC) Wojciech G Polak, MD, PhD, FEBS Department of Surgery, Division of HPB and Transplant Surgery, Erasmus MC, University Medical Center Rotterdam the
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationSmall Hepatocellular Carcinoma: Comparison of Radio-frequency Ablation and Percutaneous Microwave Coagulation Therapy 1
Vascular and Interventional Radiology Toshiya Shibata, MD Yuji Iimuro, MD Yuzo Yamamoto, MD Yoji Maetani, MD Fumie Ametani, MD Kyo Itoh, MD Junji Konishi, MD Index terms: Liver, CT, 761.1211, 761.12112,
More informationORIGINAL ARTICLE. Treatment of Stage IVA Hepatocellular Carcinoma
ORIGINAL ARTICLE Treatment of Stage IVA Hepatocellular Carcinoma Should We Reappraise the Role of Surgery? Mircea Chirica, MD; Olivier Scatton, MD; Pierre-Philippe Massault, MD; Thomas Aloia, MD; Bruto
More informationKey words: small hepatocellular carcinoma, types of hepatic resection, surgical indication, recurrence after hepatic resection
Key words: small hepatocellular carcinoma, types of hepatic resection, surgical indication, recurrence after hepatic resection Table I Relationship between operative procedure and preoperative evaluation
More informationCorrespondence should be addressed to Masanori Matsuda;
HPB Surgery, Article ID 641685, 8 pages http://dx.doi.org/10.1155/2014/641685 Clinical Study Preoperative Gadoxetic Acid-Enhanced MRI and Simultaneous Treatment of Early Hepatocellular Carcinoma Prolonged
More informationCT Evaluation of the Progression of Hypoattenuating Nodular Lesions in Virus-Related Chronic Liver Disease
Takayasu et al. CT in Liver Disease Hepatobiliary Imaging Original Research A C M E D E N T U R I C A L I M A G I N G Kenichi Takayasu 1 Yukio Muramatsu 2 Yasunori Mizuguchi 1 Takuji Okusaka 3 Kazuaki
More informationInt J Clin Exp Med 2015;8(1): /ISSN: /IJCEM
Int J Clin Exp Med 2015;8(1):1035-1042 www.ijcem.com /ISSN:1940-5901/IJCEM0003751 Original Article Pure transcatheter arterial chemoembolization therapy for intrahepatic tumors causes a shrink in pulmonary
More informationHepatocellular Carcinoma in Qatar
Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study
More informationInverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma
DOI:10.1111/j.1477-2574.2012.00507.x HPB ORIGINAL ARTICLE Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma Umut Sarpel 1, Diego Ayo 2, Iryna Lobach 3, Ruliang Xu 4
More informationActual 10-year survival following hepatectomy for hepatocellular carcinoma
DOI:10.1111/hpb.12206 HPB ORIGINAL ARTICLE Actual 10-year survival following hepatectomy for hepatocellular carcinoma Bernardo Franssen, Ghalib Jibara, Parissa Tabrizian, Myron E. Schwartz & Sasan Roayaie
More informationPrediction of Hepatocellular Carcinoma Incidence Risk by Ultrasound Elastography
2235-1795/14/0031-0001$39.50/0 1 Editorial Prediction of Hepatocellular Carcinoma Incidence Risk by Ultrasound Elastography Prof. M. Kudo Editor Liver Cancer In patients with chronic hepatitis and continuous
More informationAnalysis of efficacy and safety of TACE in combination with RFA and MWA in the treatment of middle and large primary hepatic carcinoma
JBUON 2019; 24(1): 163-170 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Analysis of efficacy and safety of TACE in combination with RFA and
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More information